Author: Ravi Shankar

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN; NYSE TX: ORN) (the “Company” or “Orion”), a leading specialty construction company, today announced that management will participate in the following investor conferences:

• 17^th Annual Craig-Hallum Alpha Select Conference on November 17, 2026, in New York, NY
• 15^th Annual ROTH Deer Valley Event on December 10-11, 2026, in Deer Valley, UT

About Orion Group Holdings
Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas. The Company’s website is located at: https://www.oriongroupholdingsinc.com.

Contact:
Margaret Boyce
346-278-3762
mboyce@orn.net

Source: Orion Group Holdings, Inc.

SANTA CRUZ, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — The Board of Directors of West Coast Community Bancorp (the “Company”) (Nasdaq: WCCB), the parent company of West Coast Community Bank, announced the approval of a new share repurchase program. Under the share repurchase program, the Company is authorized to repurchase up to $25 million of the Company’s common stock in the open market or through privately negotiated transactions as market conditions warrant. The program does not obligate the Company to repurchase any specified number of shares.

The timing and price of repurchases as well as the actual number of shares repurchased under the program will be at the discretion of the Company and will depend on a variety of factors, including general market conditions, the stock price, regulatory requirements and limitations, corporate liquidity requirements and priorities and other factors. The share repurchase program expires December 31, 2028.

“This share repurchase program reflects our confidence in the strength of our balance sheet and the long-term value of our Company,” said Krista Snelling, Chairman and Chief Executive Officer of West Coast Community Bancorp. “The program represents a disciplined and strategic use of capital, reinforcing our commitment to enhancing shareholder value while maintaining flexibility to invest in future growth.”

The Company intends to fund repurchases from its presently held internal funds, supplemented as needed by a dividend from West Coast Community Bank, and to execute repurchases in compliance with applicable federal and state securities laws and bank regulations, including without limitation, Rules 10b-18 and 10b5-1 promulgated under the Securities and Exchange Act of 1934, as amended. The stock repurchase program may be suspended, terminated or modified any time without notice. The program is subject to customary regulatory approvals or non-objections.

ABOUT WEST COAST COMMUNITY BANCORP AND WEST COAST COMMUNITY BANK

West Coast Community Bancorp is the bank holding company for West Coast Community Bank. Founded in 2004, the Bank is a top-rated, locally operated and full-service community bank headquartered in Santa Cruz, Calif. with branches in Aptos, Capitola, King City, Monterey, Salinas, San Jose, San Luis Obispo, San Mateo, Santa Cruz, Scotts Valley and Watsonville. West Coast Community Bank is distinguished from “big banks” by its relationship-based service, problem-solving focus and direct access to decision makers. The Bank also is an SBA Preferred Lending Partner. As a full-service bank, West Coast Community Bank offers competitive deposit and lending solutions for businesses and individuals; including business loans, lines of credit, commercial real estate financing, construction lending, asset-based lending, agricultural loans, SBA and USDA government guaranteed loans, credit cards, merchant services, remote deposit capture, mobile and online banking, bill payment and treasury management. True to its community roots, West Coast Community Bank supports regional well-being by actively participating in and donating to local nonprofit organizations. Visit www.wccb.com for more information.

Forward-Looking Statements

This release may contain statements that we believe are, or may be considered to be, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions of the Company. All statements other than statements of historical fact included in this release may constitute forward-looking statements, including statements regarding the prospects of our industry or our prospects, plans, expected operating results, financial position or business strategy. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as “plan,” “expect,” “look forward to,” “budget,” “scheduled,” “estimate,” “forecast,” “continue,” “intend,” “potential,” “anticipate,” “believe,” “should,” “may,” “could,” “would,” “might,” “seek,” “will,” “be taken,” “occur,” “be achieved” or the negative of these terms or variations of them or similar terms. These forward-looking statements include, without limitation, statements related to terms, timing, logistics and conditions of the Company’s share repurchase program, the Company’s utilization of the share repurchase program, and the Company’s compliance with applicable federal and state securities laws and bank regulations in connection with the administration of the share repurchase program. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those reflected in these forward-looking statements. Such risks and uncertainties may include but are not necessarily limited to fluctuations in interest rates (including but not limited to changes in depositor behavior and/or impacts on our core deposit intangible in relation thereto), inflation, government regulations and general economic conditions and competition within the business areas in which the Company and the Company’s clients are conducting their operations, including the impact of proposed or imposed tariffs or other trade restrictions, labor or supply chain issues, health of the real estate market in California, the Company’s ability to effectively execute its business plans, other factors beyond the Company’s control and those risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), which are available on the Investor Relations page of our website at investors.wccb.com and on the SEC’s website at www.sec.gov. Therefore, we caution you not to place undue reliance on any forward-looking statements contained herein, which reflect management’s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements.

MEDIA CONTACTS
Krista Snelling, Chairman and Chief Executive Officer
Cecilia Situ, Executive Vice President and Chief Financial Officer
investorrelations@wccb.com

EL SEGUNDO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein Company™ (the “Company”), announced today that on November 11, 2026, the Human Capital Management and Compensation Committee of the Company’s Board of Directors (the “Committee”) granted 101,351 restricted stock units (“RSUs”) to Brijesh Krishnaswamy in connection with Mr. Krishnaswamy’s hiring and appointment as the Company’s Chief Operating Officer, and 84,459 RSUs to Adriaan Figee in connection with Mr. Figee’s hiring and appointment as the Company’s General Manager, EMEA, in each case, under the Beyond Meat, Inc. 2026 Employment Inducement Equity Incentive Plan (the “2026 Inducement Plan”). The awards were granted as inducements material to Messrs. Krishnaswamy and Figee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest as to 1/4^th of the RSUs on the one-year anniversary of the applicable vesting commencement date and as to 1/16^th of the RSUs on each three-month anniversary of the vesting commencement date thereafter, such that the RSUs will be fully vested on the four-year anniversary of the vesting commencement date, subject to continued employment with the Company on such vesting dates. The awards are subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of an RSU agreement covering the grant.

The 2026 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company or its parent or subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).

About Beyond Meat
Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein Company™, is a plant protein company offering a portfolio of plant-based products made from simple ingredients without GMOs, no added hormones or antibiotics, and 0mg of cholesterol per serving. Founded in 2009, Beyond Meat’s core products are designed to have the same taste and texture as animal-based meat while being better for people and the planet. The Company’s brand promise, Eat What You Love^®, represents a strong belief that there is a better way to feed our future and that the positive choices we all make, no matter how small, can have a great impact on our personal health and the health of our planet. By shifting from animal-based protein to plant-based protein, we can positively impact four growing global issues: human health, climate change, constraints on natural resources and animal welfare. Visit www.BeyondMeat.com and follow @BeyondMeat on Facebook, Instagram, Threads and LinkedIn.

Contacts
Media:
Shira Zackai
shira.zackai@beyondmeat.com

Investors:
Raphael Gross
beyondmeat@icrinc.com

• ROLR^™ prediction markets platform launched to the public on October 21 and began generating revenue in the fourth quarter; the ROLR iOS app has been available in the Apple App Store since November 9
• No outstanding borrowings and $13.4 million in cash and cash equivalents at September 30, 2026
• Conference call today, November 13, at 4:30 p.m. ET

LAS VEGAS, Nevada, Nov. 13, 2026 (GLOBE NEWSWIRE) — High Roller Technologies, Inc. (“High Roller” or the “Company”) (NYSE American: ROLR), a prediction markets and online gaming company, today reported its financial results for the third quarter ended September 30, 2026, and provided an update on the commercial launch and continued development of its ROLR^™ prediction markets business. High Roller will host a conference call today at 4:30 p.m. Eastern Time (ET) to discuss third quarter results and provide a business update.

Management Commentary

“On October 21, our ROLR prediction markets platform went live to the public, and High Roller formally entered its next chapter,” said Seth Young, Chief Executive Officer of High Roller Technologies. “The ROLR iOS app launched in the Apple App Store on November 9, and we plan to release our Android app in Q4 2026. We believe prediction markets have the potential to become the major growth driver for High Roller in 2027.”

“Now our job is to bring customers onto the platform, learn from every trade, keep improving the product and put our distribution partners to work,” continued Young. “Since High Roller was founded in 2021, we believe the Company has demonstrated a track record of generating a positive return on customer acquisition ad spend across the markets and verticals it has operated in. We control our product roadmap, we’ve added proven leaders on product and partnerships, and we have another new product release planned before the end of November, among other strategic initiatives. Meanwhile, our team has managed the online casino business with real discipline through a deliberate strategic shift, and we expect Q3 2026 to be the last quarter in which prediction markets appear only on the expense side of the ledger. We’re confident in our playbook, and we’re playing to win.”

“Our Q3 2026 results reflect lower online casino revenue due to the year-over-year impact of having exited certain markets in 2025, as well as our continued investment to bring ROLR to market,” said Adam Felman, Chief Financial Officer of High Roller Technologies. “The casino customers we serve today are more valuable, with revenue per depositing customer more than doubling year over year. We ended the quarter with $13.4 million in cash and cash equivalents and no outstanding borrowings, which we believe is sufficient to fund our operations for at least the next twelve months.”

Prediction Markets Industry Outlook and Strategic Overview

Prediction markets bring together participants trading on outcomes across sports, financial markets, politics, entertainment and other real-world events. The industry has expanded rapidly: in a September 2026 note reported by The Block, Bernstein analysts estimated 2026 prediction market trading volume of approximately $410 billion and projected that annual volume could reach $10 trillion by 2035.¹

High Roller’s strategy is to capture share of this growing market by combining access to event contracts offered through regulated exchange infrastructure with a consumer experience the Company controls, relevant market information and established digital distribution relationships. Management believes product quality, effective customer acquisition and retention, and responsible, compliant participation will be central to building the ROLR business.

Recent Strategic and Corporate Highlights

Third Quarter Developments

• Launched the invitation-only ROLR beta on September 15 to test the customer experience and operating infrastructure ahead of commercial availability.
• On August 13, entered into a platform and source code license and development agreement with DeepEther Labs, Ltd., the company behind mrkts.com, securing technology rights, dedicated development resources and ownership of the customer-facing ROLR application.
• Appointed Ben Sutherland as Senior Vice President, Product and Platform. Mr. Sutherland previously served as CEO of Greentube USA, the U.S. arm of NOVOMATIC’s digital gaming group, where he led U.S. operations and P&L across a multi-jurisdictional regulated footprint. Previously, Mr. Sutherland co-founded and managed Present Creative, an international game studio that produced more than 100 titles and live releases for partners including Disney, EA, Zynga, and Microsoft. NOVOMATIC’s Greentube acquired Present Creative in 2022.

Developments After Third Quarter End

• Commercially launched ROLR on October 21 for eligible U.S. customers. ROLR US LLC operates as a registered guaranteed introducing broker; customer accounts are carried by Crypto.com FCM.
• Appointed Flip Pidot, CFA, as Chief Business Officer, as announced October 13, to lead business development and strategic partnerships.
• Highlighted the ROLR Election Tracker at elections.rolr.com on November 2, featuring prediction market odds, interactive race maps and congressional-control indicators for the 2026 U.S. midterms.
• Supported the commercial rollout through marketing relationships with Lines.com, Forever Network, Leverage Game Media and the Company’s affiliated marketing partner Spike Up Media, alongside participation in industry and investor conferences.
• Registered with the National Futures Association as a commodity trading advisor, ahead of a new product release planned for later in November.
• Launched the ROLR iOS app in the Apple App Store on November 9, giving eligible customers mobile access to market discovery, trading and account management. An Android app is planned for release through Google Play before year-end.
• Announced on November 11 the formation of ROLR FCM LLC and the engagement of Connamara Technologies to advise the Company as it explores a potential application for registration as a Futures Commission Merchant (FCM) with the CFTC and NFA. Entity formation is a preliminary step; it is not an FCM application and does not authorize FCM operations, and there can be no assurance as to the timing or outcome of any registration.
• Announced on November 12 a commercial agreement with ProphetX intended to expand the range of event contracts available to eligible ROLR customers. The agreement becomes effective six months after ROLR FCM LLC receives FCM registration, unless the parties agree otherwise, and remains subject to integration and applicable regulatory requirements. The Company has not applied for FCM registration, and there can be no assurance that such registration will be obtained or that the agreement will become effective.
• Partnered with Kindbridge Behavioral Health to provide quarterly training for the Company’s customer-service team and a confidential pathway to care for eligible U.S.-based customers, including a planned Trader Care Fund to help eligible at-risk customers access treatment.

Third Quarter 2026 Financial Results Summary

• Net revenues were $2.4 million, down $2.5 million, or 51%, from $4.9 million in the third quarter of 2025, reflecting the year-over-year impact of markets exited and a revised marketing strategy. Prediction markets generated no third-quarter revenue.
• Average revenue per unique depositing customer was $507, more than double the $242 in the third quarter of 2025, reflecting the Company’s focus on higher-value players.
• Total operating expenses were $5.1 million, down $0.4 million, or 8%, from $5.6 million in the third quarter of 2025. Lower direct operating costs were partially offset by higher spending to prepare for the prediction markets launch.
• Loss from operations was $2.7 million, compared with a loss from operations of $0.7 million in the third quarter of 2025.
• Net loss from continuing operations was $2.8 million, or $(0.25) per basic and diluted share, versus income of $2.9 million, or $0.34 basic and $0.31 diluted, a year earlier. The prior-year quarter included a $3.6 million income tax benefit, primarily from the release of a valuation allowance on deferred tax assets of a Maltese subsidiary, versus $0.2 million of tax expense in the third quarter of 2026. Loss before income taxes was $2.6 million, compared with $0.8 million a year earlier.
• Total net loss was $2.8 million, or $(0.25) per basic and diluted share, versus income of $3.7 million, or $0.43 basic and $0.39 diluted, a year earlier. Prior-year income included $0.8 million from discontinued operations.
• Adjusted EBITDA was negative $2.1 million, versus negative $0.2 million a year earlier. See Non-GAAP Financial Measures below for reconciliations.
• Cash and cash equivalents excluding restricted cash were $13.4 million and stockholders’ equity was $27.3 million at September 30, 2026.
• In October 2026, the Company filed amended quarterly reports for the first and second quarters of 2026 to correct the accounting for approximately $1.0 million of non-cash placement-agent warrant costs. The amendment reduced previously reported net losses, and had no effect on revenue, cash, total stockholders’ equity or Adjusted EBITDA.

Additional information regarding the Company’s results of operations, financial condition and liquidity is included in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which the Company filed with the U.S. Securities and Exchange Commission on November 13, 2026.

Conference Call

High Roller will host a conference call to provide a business update and discuss third quarter results today, November 13, 2026, at 4:30 p.m. ET.

To join the live conference call, please dial 877-407-6176 (U.S. and Canadian callers) or +1 201-689-8451 (international callers outside of the U.S. and Canada) 10 to 15 minutes prior to the scheduled call time. Participants can also click this link for instant telephone access to the event. The link will become active approximately 15 minutes prior to the start of the conference call. The conference ID# is 13763816.

About High Roller Technologies, Inc.

High Roller Technologies, Inc. (NYSE American: ROLR) is a publicly traded prediction markets and online gaming company, known for its innovative casino brands High Roller and Fruta, and its prediction markets brand, ROLR. The Company delivers cutting-edge real-money consumer facing products that are intuitive and user-friendly. With a diverse portfolio of over 6,000 premium online casino games from more than 90 leading game providers, High Roller Technologies offers an immersive and engaging gaming experience in the rapidly expanding multi-billion-dollar iGaming industry. As an award-winning operator, High Roller Technologies continues to redefine the future of market engagement through innovation, performance, and a commitment to excellence.

For more information, please visit the Company’s investor relations website and follow High Roller Technologies on X, Facebook, and LinkedIn.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Words such as “may,” “might,” “will,” “should,” “could,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” “target,” “seek,” “potential” or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, among others, statements regarding the commercial launch, growth and revenue generation of the ROLR^™ prediction markets platform, including our belief that prediction markets may become a major growth driver in 2027; the planned release of an Android app and other new products; the expected further decline in online casino revenue; the sufficiency of our cash and cash equivalents to fund operations for at least the next twelve months; our exploration of potential registration of ROLR FCM LLC as a futures commission merchant; the expected effectiveness and benefits of our agreement with ProphetX; our marketing, distribution and responsible-gaming initiatives, including the planned Trader Care Fund; and industry growth estimates.

Forward-looking statements are neither historical facts nor assurances of future performance. They are based only on our current beliefs, expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results, financial condition and the timing of events may differ materially from those indicated in the forward-looking statements, and you should not place undue reliance on them. Important factors that could cause such differences include, among others: our limited operating history in the prediction markets business, our history of losses and our continued use of cash; risks related to platform stability, scalability, cybersecurity and technical performance; our ability to attract, convert and retain customers and to generate revenue from the platform in the anticipated timeline or at all; the cost and effectiveness of our marketing and customer-acquisition efforts and the performance of our marketing and distribution partners, including a related-party marketing partner; our reliance on third parties, including Crypto.com | Derivatives North America, Crypto.com FCM, DeepEther Labs, Ltd. (mrkts.com), and the continuation of our guarantee, license, development and commercial agreements; the risk that the ProphetX agreement does not become effective, including because FCM registration is not obtained; our ability to maintain the registration of ROLR US LLC as a guaranteed introducing broker, our registration as a commodity trading advisor and our membership in the National Futures Association; the uncertain timing and outcome of any FCM registration process, which may not be pursued or approved; the evolving and uncertain federal and state legal and regulatory environment applicable to prediction markets and event contracts, including litigation and enforcement actions; the impact of our exit from New Zealand and other markets on our online casino revenue; our ability to raise additional capital on acceptable terms, if needed; the restatement of our 2026 interim financial statements and the effectiveness of our internal control over financial reporting; the accuracy of third-party industry estimates, which we have not independently verified; and general market, economic and geopolitical conditions.

These and other factors are discussed under Part I, Item 1A. “Risk Factors” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2025, Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A. “Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, our amended Quarterly Reports on Form 10-Q/A for the quarters ended March 31, 2026 and June 30, 2026, and our other filings with the Securities and Exchange Commission. Any forward-looking statement in this press release speaks only as of the date of this press release and is based only on information currently available to us. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

This press release includes Adjusted EBITDA, which is a non-GAAP financial measure that the Company uses to supplement its results presented in accordance with U.S. GAAP. The Company believes this measure is useful in evaluating operating performance and trends and in making strategic decisions regarding the allocation of capital and new investments. This measure is not intended to be a substitute for any U.S. GAAP financial measure and may not be comparable to similarly titled measures used by other companies.

The Company defines Adjusted EBITDA as net loss from continuing operations before the impact of interest income and expense, income tax provision or benefit, and depreciation and amortization, and further adjusted for the following items: stock-based compensation; and certain other costs or income, as described in the reconciliation below. The most directly comparable U.S. GAAP measure is net income (loss) from continuing operations.

Contact
Investor Relations
ir@highroller.com
800-460-1039

¹ The Block, “Bernstein sees annual prediction market volumes hitting $10 trillion by 2035 as financial assets overtake sports,” September 22, 2026.

HIGH ROLLER TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
(in thousands, except share and per share data)		2026				2025				2026				2025
Revenues, net		$	2,395			$	4,858			$	8,570			$	15,803
Operating expenses
Direct operating costs:
Related party			97				258				430				879
Other			711				1,725				2,826				6,482
General and administrative:
Related party			—				2				—				132
Other			3,050				2,816				9,927				8,967
Advertising and promotions:
Related party			541				92				940				935
Other			468				456				938				3,238
Product and software development:
Related party			—				—				—				—
Other			247				212				693				602
Total operating expenses			5,114				5,561				15,754				21,235
Loss from operations			(2,719	)			(703	)			(7,184	)			(5,432	)
Other income (expense)
Interest income (expense), net			115				(55	)			307				(154	)
Other income (expense)			8				—				(5	)			(1	)
Total other income (expense)			123				(55	)			302				(155	)
Loss before income taxes			(2,596	)			(758	)			(6,882	)			(5,587	)
Income tax expense (benefit)			184				(3,641	)			231				(3,588	)
Net income (loss) from continuing operations		$	(2,780	)		$	2,883			$	(7,113	)		$	(1,999	)
Net income from discontinued operations, net of taxes		$	—			$	784			$	—			$	1,798
Net income (loss)		$	(2,780	)		$	3,667			$	(7,113	)		$	(201	)
Other comprehensive loss
Foreign currency translation adjustment			(30	)			(50	)			(195	)			(82	)
Comprehensive income (loss)		$	(2,810	)		$	3,617			$	(7,308	)		$	(283	)
Net income (loss) per common share – basic:
Continuing operations		$	(0.25	)		$	0.34			$	(0.66	)		$	(0.24	)
Discontinued operations		$	—			$	0.09			$	—			$	0.21
Net income (loss) per common share – basic		$	(0.25	)		$	0.43			$	(0.66	)		$	(0.02	)
Net income (loss) per common share – diluted:
Continuing operations		$	(0.25	)		$	0.31			$	(0.66	)		$	(0.24	)
Discontinued operations		$	—			$	0.08			$	—			$	0.21
Net income (loss) per common share – diluted		$	(0.25	)		$	0.39			$	(0.66	)		$	(0.02	)
Weighted average common shares outstanding – basic			11,002,788				8,467,841				10,782,481				8,424,869
Weighted average common shares outstanding – diluted			11,002,788				9,352,863				10,782,481				8,424,869

Per share amounts may not sum due to rounding.

HIGH ROLLER TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

		As of				As of
		September 30,				December 31,
(in thousands, except share and per share data)		2026				2025
			(Unaudited)
Assets
Current assets
Cash and cash equivalents		$	13,392			$	2,076
Restricted cash			428				589
Prepaid expenses and other current assets (including $333 and $0 with a related party, respectively)			2,192				779
Deferred tax asset, current			—				2,368
Total current assets			16,012				5,812
Non-current assets
Deferred offering costs			—				80
Property and equipment, net			336				417
Operating lease right-of-use asset, net			648				826
Intangible assets, net			13,879				10,507
Deferred tax asset, non-current			3,064				817
Other assets			99				60
Total assets		$	34,038			$	18,519
Liabilities and stockholders’ equity
Current liabilities
Accounts payable		$	643			$	804
Accrued expenses			1,797				3,373
Player liabilities			779				816
Due to affiliates			1,604				1,993
Operating lease obligation, current			224				166
Total current liabilities			5,047				7,152
Other liabilities			1,237				1,084
Operating lease obligation, non-current			469				641
Total liabilities			6,753				8,877
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of September 30, 2026 and December 31, 2025			—				—
Common stock, $0.001 par value; 60,000,000 shares authorized; 10,994,564 shares and 8,485,405 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively			11				8
Additional paid-in capital			57,878				32,930
Accumulated deficit			(31,412	)			(24,299	)
Accumulated other comprehensive income			808				1,003
Total stockholders’ equity			27,285				9,642
Total liabilities and stockholders’ equity		$	34,038			$	18,519

HIGH ROLLER TECHNOLOGIES, INC. AND SUBSIDIARIES
GAAP NET INCOME (LOSS) FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA (UNAUDITED)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
(in thousands)		2026				2025				2026				2025
Revenues		$	2,395			$	4,858			$	8,570			$	15,803
Net income (loss) from continuing operations			(2,780	)			2,883				(7,113	)			(1,999	)
Add back items:
Stock-based compensation expense (1)			421				333				1,108				1,142
Depreciation and amortization (2)			99				97				239				257
Interest (income) expense, net			(115	)			55				(307	)			154
Income tax expense (benefit)			184				(3,641	)			231				(3,588	)
Foreign exchange transaction loss			97				91				277				421
Other (3)			—				20				385				276
Adjusted EBITDA		$	(2,094	)		$	(162	)		$	(5,180	)		$	(3,337	)

(1) Represents non-cash share-based compensation expense for stock options, restricted stock units (including performance-based restricted stock units) and shares of common stock issued for services, granted to employees, directors and consultants.

(2) Includes amortization of intangible assets generated through business acquisitions and depreciation of property and equipment, amortization of contract costs, and amortization of internally developed software and other intangible assets. Excludes amortization of right of use assets.

(3) Includes severance costs and non-recurring executive bonuses paid in the first quarter of 2026.

$30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financing

ATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.

Corporate Highlights from 3Q 2026 to date

• Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed^® fertility portfolio to OB/GYNs, and to fund the FemBloc^® pivotal trial to support U.S. approval.
• Highlights for the FemaSeed Fertility Portfolio (Diagnostics: FemVue^® for her and SpermVue^TM for him; first-step treatment: FemaSeed and FemSperm^®):
  • Announced a partnership with both UNC Health and Minnesota Women’s Care to introduce the entire portfolio across its OB/GYN practice locations.
  • Announced a partnership with CapexMD to expand patient access through financing solutions and SandsRx Pharmacy for medications to support treatment timing.
• Highlights for FemBloc Permanent Birth Control:
  • Issuance of patents in the U.S. and key international markets that expand intellectual property protection for the blended polymer component.
  • Received FDA approval of the modular premarket approval (PMA) submission approach.
  • Announced the number of actively enrolling sites in the FINALE trial to support U.S. approval doubled to twelve sites.

“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “With U.S. fertility rates at historic lows, there is an urgent need to bring treatment to the OB/GYN office, where women already seek care. Our portfolio enables these physicians to offer a complete pathway from diagnostics through first-step treatment, supported by partnerships that simplify access to patient financing and fertility medications. Since closing the financing, we have been successfully recruiting commercial professionals with deep OB/GYN expertise and established relationships. Healthcare system partnerships and initial sales achieved with limited resources demonstrate the commercial potential of our comprehensive fertility portfolio. These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”

Financial Results for Quarter Ended September 30, 2026

• Sales in the U.S. increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 from $729,394. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.
• Research and development expenses increased by $560,905, or 40.6%, to $1,942,927 in 2026 compared to $1,382,022 in 2025, primarily reflecting the transition of development products into inventory to support commercialization during 2025, and increased clinical costs and compensation costs during 2026.
• Net loss was $4,564,815, or ($0.53) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of $4,194,821, or ($2.05) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2025.

Financial Results for Nine Months Ended September 30, 2026

• Sales in the U.S. increased slightly to $1,038,997 in 2026 from $1,015,168 in 2025, while overall sales decreased by $318,613, or 21.5%, to $1,161,313 from $1,479,926. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.
• Research and development expenses decreased by $565,717, or 9.8%, to $5,199,206 in 2026 compared to $5,764,923 in 2025, primarily reflecting lower compensation costs, regulatory fees and outside consultant costs, partially offset by increased clinical costs and material and development costs.
• Net loss was $8,187,810, or ($1.59) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2026, compared to a net loss of $14,677,582, or ($9.25) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2025.
• Cash and cash equivalents as of September 30, 2026, were approximately $23.9 million and the Company had an accumulated deficit of approximately $154.0 million.

For more information, please refer to the Company’s Form 10-Q filed November 13, 2026, which can be accessed on the SEC website.

FEMASYS INC.
Condensed Balance Sheets
(unaudited)
Assets							September 30, 2026			December 31, 2025
Current assets:
	Cash and cash equivalents					$	23,913,946			9,266,353
	Accounts receivable, net						233,778			616,600
	Inventory						6,166,371			5,740,249
	Prepaid and other current assets						893,098			833,133
					Total current assets		31,207,193			16,456,335
Property and equipment, at cost:
	Leasehold improvements						1,238,886			1,238,886
	Office equipment						91,610			78,155
	Furniture and fixtures						424,586			417,876
	Machinery and equipment						3,125,855			3,065,713
	Construction in progress						991,124			897,885
							5,872,061			5,698,515
Less accumulated depreciation							(3,991,222	)		(3,802,940	)
					Net property and equipment		1,880,839			1,895,575
Long-term assets:
	Lease right-of-use assets, net						952,796			1,297,121
	Intangible assets, net of accumulated amortization						99,902			134,914
	Other long-term assets						946,928			940,232
					Total long-term assets		1,999,626			2,372,267
					Total assets	$	35,087,658			20,724,177
(continued)

FEMASYS INC.
Condensed Balance Sheets
(unaudited)
Liabilities and Stockholders’ Equity							September 30, 2026			December 31, 2025
Current liabilities:
	Accounts payable					$	1,958,546			1,830,124
	Accrued expenses						855,377			1,265,773
	Note payable						292,229			—
	Clinical holdback – current portion						29,250			52,644
	Operating lease liabilities – current portion						465,960			487,624
					Total current liabilities		3,601,362			3,636,165
Long-term liabilities:
	Clinical holdback – long-term portion						58,179			52,370
	Convertible notes payable, net						3,717,653			3,178,864
	Conversion option liability						—			2,014,000
	Warrants liabilities						—			4,943,000
	Operating lease liabilities – long-term portion						682,302			1,030,476
					Total long-term liabilities		4,458,134			11,218,710
					Total liabilities		8,059,496			14,854,875
Commitments and contingencies
Stockholders’ equity:
	Common stock, $0.001 par, 200,000,000 shares authorized,
		8,662,139 shares issued and 8,656,277 shares outstanding as of
		September 30, 2026; and 2,986,116 shares issued
		and 2,980,254 shares outstanding as of December 31, 2025					8,662			2,986
	Treasury stock, 5,862 common shares						(60,000	)		(60,000	)
	Warrants						19,023,695			5,246,150
	Additional paid-in capital						162,069,759			146,506,310
	Accumulated deficit						(154,013,954	)		(145,826,144	)
					Total stockholders’ equity		27,028,162			5,869,302
					Total liabilities and stockholders’ equity	$	35,087,658			20,724,177

FEMASYS INC.
Condensed Statements of Operations
(unaudited)
							Three Months Ended September 30,						Nine Months Ended September 30,
							2026			2025			2026			2025
Sales						$	404,597			729,394			1,161,313			1,479,926
Cost of sales (excluding depreciation expense)							187,496			293,838			488,538			569,275
Operating expenses:
	Research and development						1,942,927			1,382,022			5,199,206			5,764,923
	Sales and marketing						943,002			1,143,805			3,552,755			3,037,349
	General and administrative						1,704,091			1,477,800			5,418,059			4,817,485
	Depreciation and amortization						77,091			85,697			242,172			256,835
					Total operating expenses		4,667,111			4,089,324			14,412,192			13,876,592
					Loss from operations		(4,450,010	)		(3,653,768	)		(13,739,417	)		(12,965,941	)
Other income (expense):
	Interest income						85,610			17,315			155,131			53,488
	Change in fair value of Conversion Option liability						—			—			1,732,413			—
	Change in fair value of Warrants liabilities						—			—			4,228,000			—
	Interest expense						(200,415	)		(532,073	)		(563,072	)		(1,483,022	)
	Other expense						—			(26,295	)		—			(286,295	)
					Total other income (expense), net		(114,805	)		(541,053	)		5,552,472			(1,715,829	)
					Loss before income taxes		(4,564,815	)		(4,194,821	)		(8,186,945	)		(14,681,770	)
	Income tax expense (benefit)						—			—			865			(4,188	)
					Net loss	$	(4,564,815	)		(4,194,821	)		(8,187,810	)		(14,677,582	)
Net loss attributable to common stockholders						$	(4,564,815	)		(4,194,821	)		(8,187,810	)		(14,677,582	)
Basic and diluted loss per share						$	(0.53	)		(2.05	)		(1.59	)		(9.25	)
Weighted-average common shares and pre-funded warrants outstanding, basic and diluted							8,660,381			2,050,761			5,136,109			1,586,992

About Femasys Inc.
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed^® Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc^®, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
IR@femasys.com
Media@femasys.com

• Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027
• TRB-071 advancing through IND-enabling studies, with Phase 1 trial initiation expected in the first half of 2027
• Completed a $133.5 million initial public offering in October 2026, extending expected cash runway into the second half of 2029

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today reported financial results for the third quarter ended September 30, 2026, and provided recent business highlights and anticipated development milestones.

“Our approach begins with understanding how regulatory T cells function in human tissues and using those insights to develop medicines intended to address the underlying immune dysfunction in disease,” said Johnston Erwin, Chief Executive Officer of TRexBio. “The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis. With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”

Recent Business and Corporate Highlights

TRB-061: TNFR2 Agonist in Phase 1 Clinical Development for Atopic Dermatitis

• Reported positive Phase 1a topline results supporting proof of mechanism: In August 2026, TRexBio announced positive topline results from the Phase 1a portion of its ongoing Phase 1a/b clinical trial of TRB-061 in healthy volunteers. TRB-061 was generally well tolerated across all dose levels, with no treatment-related serious adverse events or dose-limiting toxicities observed. Results demonstrated consistent pharmacokinetics and reproducible activation and expansion of immunoregulatory Tregs, supporting proof of mechanism and dose selection for the ongoing Phase 1b trial.
• Advancing Phase 1b clinical trial in atopic dermatitis: TRexBio continues to evaluate TRB-061 in patients with moderate-to-severe atopic dermatitis. The Phase 1b portion of the trial is assessing safety, pharmacokinetics, pharmacodynamic biomarkers in blood and skin, and exploratory measures of clinical activity. Topline data are expected in mid-2027.

TRB-071: CD30 Agonist in IND-Enabling Development

• Progressing toward clinical development: TRB-071, an investigational CD30 agonist antibody designed to augment tissue Tregs and block inflammatory signaling pathways, continues to advance through IND-enabling studies. Subject to regulatory allowance to proceed, TRexBio expects to initiate a Phase 1 clinical trial in the first half of 2027.

Partnered Programs

• Eli Lilly collaboration: TRB-051, a program developed through TRexBio’s research collaboration with Eli Lilly and Company, is in clinical development. Lilly intends to advance TRB-051 into a Phase 2a clinical trial in lupus with cutaneous involvement.

Corporate Highlights

• Completed initial public offering: In October 2026, TRexBio completed its IPO of 9,539,237 shares of common stock at a public offering price of $14.00 per share, including 1,205,903 shares sold upon the underwriters’ partial exercise of their option to purchase additional shares. Gross proceeds were approximately $133.5 million, and net proceeds were approximately $119.0 million, after deducting underwriting discounts and commissions and estimated offering expenses. TRexBio’s common stock trades on the Nasdaq Global Select Market under the ticker symbol “TRXB.”

Third Quarter 2026 Financial Results

• Cash Position and Cash Runway: Cash, cash equivalents and marketable securities totaled $78.2 million as of September 30, 2026, excluding approximately $119.0 million in net proceeds from the IPO completed in October 2026. Based on its current operating plan, TRexBio expects these resources, together with the IPO net proceeds, to fund operations and capital expenditure requirements into the second half of 2029.
• Research and Development (R&D) Expenses: R&D expenses were $11.4 million for the third quarter of 2026, compared to $7.0 million for the third quarter of 2025. The increase was primarily driven by higher clinical trial costs associated with TRB-061, increased preclinical development and manufacturing activities for TRB-071 and other product candidates, and higher personnel and facility-related costs.
• General and Administrative (G&A) Expenses: G&A expenses were $2.5 million for the third quarter of 2026, compared to $1.7 million for the third quarter of 2025. The increase was primarily attributable to higher personnel-related expenses and professional fees, including accounting and audit costs associated with preparations to operate as a public company.
• Net Loss: Net loss was $13.2 million for the third quarter of 2026, compared to $7.9 million for the third quarter of 2025.

About TRexBio

TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio’s Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California. For more information, visit www.trex.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding TRexBio’s business strategy, clinical and preclinical development programs, anticipated milestones and financial outlook. These statements include, without limitation, expectations regarding the development, potential therapeutic benefits and clinical advancement of TRB-061, TRB-071 and partnered programs; the timing and availability of clinical trial results, including topline data from the Phase 1b trial of TRB-061 in mid-2027; the anticipated initiation of a Phase 1 clinical trial of TRB-071 in the first half of 2027; and the sufficiency of TRexBio’s cash, cash equivalents, marketable securities and IPO proceeds to fund its operations and capital expenditure requirements into the second half of 2029.

Forward-looking statements are based on current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to: TRexBio’s limited operating history, lack of products approved for commercial sale, incurrence of substantial losses since its inception and anticipation of incurring substantial and increasing losses for the foreseeable future; TRexBio’s need for substantial additional financing to achieve its goals; the uncertainty of clinical development, which is lengthy and expensive, and the risk that results of earlier studies and trials may not be predictive of future trial results or results in other indications; risks related to additional costs or delays in completing, or failing to complete, the development, approval and commercialization of TRexBio’s current or future product candidates in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than TRexBio seeks; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by TRexBio’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in TRexBio’s current indications; risks related to the material weakness identified in TRexBio’s internal control over financial reporting; TRexBio’s ability to realize the benefits of its current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; TRexBio’s dependence on the services of its senior management and other clinical and scientific personnel, and its ability to retain these individuals or recruit additional management or clinical and scientific personnel; TRexBio’s ability to grow its organization and manage its growth and expansion of its operations; risks related to the manufacturing of TRexBio’s product candidates, which is complex; TRexBio’s ability to obtain and maintain sufficient intellectual property protection for its product candidates or any future product candidates; TRexBio’s reliance on third parties to conduct its preclinical studies and clinical trials; risks related to the operations of TRexBio’s suppliers, many of which are located outside of the United States; and other risks and uncertainties described in TRexBio’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” in its final prospectus for its initial public offering, filed with the SEC on October 9, 2026, as well as the other information TRexBio files with the SEC. TRexBio cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date of this press release. TRexBio undertakes no obligation to update these statements except as required by law. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

TRex Bio, Inc.
Condensed Statements of Operations
(In thousands) | Unaudited

	Three Months Ended September 30						Nine Months Ended September 30
		2026			2025			2026			2025
Operating expenses:
Research and development		$11,429			$6,969			$37,459			$21,935
General and administrative		2,487			1,744			7,475			6,002
Total operating expenses		13,916			8,713			44,934			27,937
Loss from operations		(13,916	)		(8,713	)		(44,934	)		(27,937	)
Interest income		768			853			2,523			2,421
Other expense, net		(3	)		–			(6	)		(66	)
Total other income, net		765			853			2,517			2,355
Loss before provision for income taxes		(13,151	)		(7,860	)		(42,417	)		(25,582	)
Provision for income taxes		88			–			130			–
Net loss		$(13,239	)		$(7,860	)		$(42,547	)		$(25,582	)

TRex Bio, Inc.
Selected Balance Sheet Data
(In thousands) | Unaudited

	Sep. 30, 2026 (1)			Dec. 31, 2025
Cash, cash equivalents and marketable securities		$78,150			$67,725
Total assets		88,755			73,133
Total liabilities		14,027			6,237
Redeemable convertible preferred stock		208,838			159,015
Total stockholders’ deficit		(134,110	)		(92,119	)

(1) The balance sheet data as of September 30, 2026, do not reflect the IPO completed in October 2026, which resulted in net proceeds of approximately $119.0 million, or the automatic conversion of all outstanding redeemable convertible preferred stock into 17,742,217 shares of common stock immediately prior to the closing of the IPO.

CONTACT: Contacts

Investor Relations: IR@trex.bio
Media Relations: jessica@litldog.com

ATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of Everyday Americans, today announced that Jeff Howard, President and Chief Executive Officer, and Bill McCamey, Chief Financial Officer, will participate in the Stephens Annual Investment Conference in Nashville, TN on November 18-19, 2026. Jeff Howard will participate in a fireside chat on Wednesday, November 18th at 11:00am.

Information regarding the conference will be available in the Events and Presentations section of the Company’s Investor Relations website at https://investors.atlanticus.com.

About Atlanticus Holdings Corporation

Empowering Better Financial Outcomes for Everyday Americans

Atlanticus Holdings Corporation empowers better financial outcomes for Everyday Americans by enabling bank, retail, and healthcare partners to offer more inclusive financial solutions to consumers. Leveraging proprietary technology and advanced analytics, Atlanticus applies more than 30 years of operating experience, servicing over 23 million customers and more than $55 billion in consumer loans, to support lenders across a broad range of consumer credit products. These offerings span retail and healthcare private-label credit and general purpose credit cards, through an omnichannel platform, including strategic partnerships.

Atlanticus is guided by the principles of responsible lending, smart innovation, and expanding access to credit for consumers working toward a stronger financial future.

Contact:
Investor Relations, investors@atlanticus.com
Dan Mauch, daniel.mauch@atlanticus.com
Sara Savarino, sara.savarino@atlanticus.com

WAUWATOSA, Wis., Nov. 13, 2026 (GLOBE NEWSWIRE) — Waterstone Financial, Inc. (NASDAQ: WSBF), holding company for WaterStone Bank, reported net income of $6.2 million, or $0.36 per diluted share, for the quarter ended September 30, 2026 compared to $7.9 million, or $0.45 per diluted share, for the quarter ended September 30, 2025. Net income totaled $20.6 million for the nine months ended September 30, 2026 compared to net income of $18.7 million for the nine months ended September 30, 2025. Net income per diluted share was $1.19 for the nine months ended September 30, 2026 compared to net income per diluted share of $1.04 for the nine months ended September 30, 2025.

“We are pleased with the hard work to reach another strong quarter with increased challenges from rising short-term and long-term treasury rates,” said William Bruss, Chief Executive Officer of Waterstone Financial, Inc. “The Community Banking segment realized another record quarterly net interest income of $16.0 million, which represented a $1.4 million increase compared to the quarter ended September 30, 2025. The increase was primarily due to a reduction of our average cost of funds, driven in part by continued growth in average transaction deposits. The Mortgage Banking segment realized a pre-tax loss of $754,000 which represents a decrease of $2.1 million compared to the quarter ended September 30, 2025. Sales margins continue to remain under pressure, following the trend from the second quarter and remaining lower than recent averages. The Mortgage Banking segment loan origination volume was hindered by a significant jump in mortgage rates. Book value per share decreased $0.24 during the quarter primarily due to treasury rates increasing negatively, impacting the value of accumulated other comprehensive losses along with declaring our quarterly dividend of $0.17 per share. We still remain in a strong capital position.”

Highlights of the Quarter Ended September 30, 2026

Waterstone Financial, Inc. (Consolidated)

• Consolidated net income of Waterstone Financial, Inc. totaled $6.2 million for the quarter ended September 30, 2026 compared to net income of $7.9 million for the quarter ended September 30, 2025.
• Consolidated return on average assets (annualized) was 1.09% for the quarter ended September 30, 2026 and 1.42% for the quarter ended September 30, 2025.
• Consolidated return on average equity (annualized) was 6.93% for the quarter ended September 30, 2026 and 9.14% for the quarter ended September 30, 2025.
• Dividends declared during the quarter ended September 30, 2026 totaled $0.17 per common share.
• Nonperforming assets as a percentage of total assets was 0.55% at September 30, 2026, 0.30% at June 30, 2026, and 0.27% at September 30, 2025.
• Past due loans as a percentage of total loans was 0.81% at September 30, 2026, 0.63% at June 30, 2026, and 0.50% at September 30, 2025.
• Book value per share was $19.29 at September 30, 2026 and $19.03 at December 31, 2025. Book value decreased approximately $0.24 during the quarter ended September 30, 2026. Of the $0.24 overall decrease, approximately $0.46 was due to the additional available for sale losses as treasury rate increases.

Community Banking Segment

• Pre-tax income totaled $8.3 million for the quarter ended September 30, 2026, which represents a $176,000, or 2.1%, decrease compared to $8.4 million for the quarter ended September 30, 2025.
• Net interest income totaled $16.0 million for the quarter ended September 30, 2026, which represents a $1.4 million, or 9.6%, increase compared to $14.6 million for the quarter ended September 30, 2025.
• Average loans held for investment totaled $1.70 billion during the quarter ended September 30, 2026, which represents an increase of $13.2 million, or 0.8%, compared to $1.68 billion for the quarter ended September 30, 2025. The increase was primarily due to increases in multi-family mortgages offset by a decrease in single-family mortgages. Average loans held for investment increased $18.5 million compared to $1.68 billion for the quarter ended June 30, 2026. The increase was primarily due to increases in multi-family mortgages offset by a decrease in single-family mortgages. See details on average loans by category in the table below.
• Net interest margin increased 30 basis points to 3.06% for the quarter ended September 30, 2026 compared to 2.76% for the quarter ended September 30, 2025, which was primarily driven by an increase in weighted average yield on loans receivable and held for sale and decreases in the cost of borrowings and weighted average cost of deposits. Net interest margin increased three basis points compared to 3.03% for the quarter ended June 30, 2026, which was primarily driven by a decrease in the weighted average cost of deposits and increases in mortgage related securities and debt securities yields.
• Past due loans at the community banking segment totaled $11.7 million at September 30, 2026, $8.5 million at June 30, 2026, and $6.8 million at September 30, 2025. The increase in past due loans and non-performing assets was related to one significant relationship which was previously identified as substandard.
• The segment had a negative provision for credit losses related to funded loans of $83,000 for the quarter ended September 30, 2026 compared to a negative provision for credit losses related to funded loans of $137,000 for the quarter ended September 30, 2025. The current quarter decrease was primarily due to a decrease in commercial real estate external qualitative risk factors offset by a $305,000 collateral dependent reserve for a loan that was previously classified as substandard. The provision for credit losses related to unfunded loan commitments was $571,000 for the quarter ended September 30, 2026 compared to a negative provision for credit losses related to unfunded loan commitments of $139,000 for the quarter ended September 30, 2025. The provision for credit losses related to unfunded loan commitments for the quarter ended September 30, 2026 was due primarily to an increase of construction and commercial real estate loans in the loan pipeline and unfunded construction balance at quarter end.
• The efficiency ratio, a non-GAAP ratio, was 49.55% for the quarter ended September 30, 2026, compared to 48.94% for the quarter ended September 30, 2025.
• Average core retail deposits (excluding brokered and escrow accounts) totaled $1.35 billion during the quarter ended September 30, 2026, an increase of $39.5 million, or 3.0%, compared to $1.31 billion during the quarter ended September 30, 2025 due primarily to increases in money market and demand deposits balances. Average core retail deposits increased $14.5 million, or 4.3% annualized, compared to $1.34 billion for the quarter ended June 30, 2026 due primarily to an increase in money market balances. The segment had an average of $80.4 million in brokered certificate of deposits during the quarter ended September 30, 2026 compared to $61.8 million during the quarter ended September 30, 2025.
• Total compensation, payroll taxes and other employee benefits increased $603,000 or 12.0%, to $5.6 million during the quarter ended September 30, 2026 compared to $5.0 million during the quarter ended September 30, 2025. The increase primarily related to increased salary expense, health insurance expense and ESOP expense as the average market price per share increased compared to the prior year.

Mortgage Banking Segment

• Pre-tax loss totaled $754,000 for the quarter ended September 30, 2026, compared to a pre-tax income of $1.3 million for the quarter ended September 30, 2025.
• Loan originations decreased $29.7 million, or 5.5%, to $509.7 million during the quarter ended September 30, 2026, compared to $539.4 million during the quarter ended September 30, 2025. Origination volume relative to purchase activity accounted for 90.4% of originations for the quarter ended September 30, 2026 compared to 90.1% of total originations for the quarter ended September 30, 2025.
• Mortgage banking non-interest income decreased $2.8 million, or 13.4%, to $18.2 million for the quarter ended September 30, 2026, compared to $21.0 million for the quarter ended September 30, 2025.
• Gross margin on loans sold totaled 3.48% for the quarter ended September 30, 2026, compared to 3.87% for the quarter ended September 30, 2025. The 10.3% decrease was driven by lower sales margins, as secondary market investors remained concerned about elevated long-term rates.
• During the quarter ended September 30, 2026, the Company sold mortgage servicing rights related to $121.9 million in loans receivable and with a book value of $1.0 million for $1.4 million resulting in a gain on sale of $391,000. There was no comparable sale during the quarter ended September 30, 2025.
• Total compensation, payroll taxes and other employee benefits decreased $993,000 or 6.3%, to $14.7 million during the quarter ended September 30, 2026 compared to $15.7 million during the quarter ended September 30, 2025. The decrease primarily related to decreased commission expense, health insurance expense, and bonus accrual.
• Total other noninterest expense increased $537,000, or 42.3%, to $1.8 million during the quarter ended September 30, 2026 compared to $1.3 million during the quarter ended September 30, 2025. The increase primarily related to an increase in provision for loan sale losses due to a pool of loans identified with additional risks to buy them back.

About Waterstone Financial, Inc.
Waterstone Financial, Inc. is the savings and loan holding company for WaterStone Bank, a community-focused financial institution established in 1921. WaterStone Bank offers a comprehensive suite of personal and business banking products and operates 14 branch locations across southeastern Wisconsin. WaterStone Bank is also the parent company of WaterStone Mortgage Corporation, a national lender licensed in 48 states.

With a long-standing commitment to innovation, integrity, and community service, Waterstone Financial, Inc. supports the financial and homeownership goals of customers nationwide. For more information about WaterStone Bank, go to wsbonline.com.

Forward-Looking Statements
This press release contains statements or information that may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding expected financial and operating activities and results that are preceded by, followed by, or that include words such as “may,” “expects,” “anticipates,” “estimates” or “believes.” Any such statements are based upon current expectations that involve a number of risks and uncertainties and are subject to important factors that could cause actual results to differ materially from those anticipated by the forward-looking statements. Factors that might cause such a difference include changes in interest rates; demand for products and services; the degree of competition by traditional and nontraditional competitors; changes in banking regulation or actions by bank regulators; changes in tax laws; the impact of technological advances; governmental and regulatory policy changes; the outcomes of contingencies; trends in customer behavior as well as their ability to repay loans; changes in local real estate values; changes in the national and local economies; and other factors, including risk factors referenced in Item 1A. Risk Factors in Waterstone’s most recent Annual Report on Form 10-K and as may be described from time to time in Waterstone’s subsequent SEC filings, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect only Waterstone’s belief as of the date of this press release.

Non-GAAP Financial Measures
Management uses non-GAAP financial information in its analysis of the Company’s performance. Management believes that this non-GAAP measure provides a greater understanding of ongoing operations and enhances comparability of results of operations with prior periods. The Company’s management believes that investors may use this non-GAAP measure to analyze the Company’s financial performance without the impact of unusual items or events that may obscure trends in the Company’s underlying performance. This non-GAAP data should be considered in addition to results prepared in accordance with GAAP, and is not a substitute for, or superior to, GAAP results. Limitations associated with non-GAAP financial measures include the risks that persons might disagree as to the appropriateness of items included in this measure and that different companies might calculate this measure differently.

WATERSTONE FINANCIAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
		For The Three Months Ended September 30,								For The Nine Months Ended September 30,
		2026				2025				2026				2025
		(In Thousands, except per share amounts)
Interest income:
Loans		$	26,955			$	26,625			$	79,516			$	77,578
Mortgage-related securities			1,506				1,365				4,439				3,809
Debt securities, federal funds sold and short-term investments			1,582				1,566				4,689				4,609
Total interest income			30,043				29,556				88,644				85,996
Interest expense:
Deposits			10,183				10,527				30,591				32,826
Borrowings			3,444				4,290				10,164				12,147
Total interest expense			13,627				14,817				40,755				44,973
Net interest income			16,416				14,739				47,889				41,023
Provision (credit) for credit losses			443				(269	)			943				(836	)
Net interest income after provision (credit) for credit losses			15,973				15,008				46,946				41,859
Noninterest income:
Service charges on loans and deposits			473				618				1,310				1,624
Increase in cash surrender value of life insurance			597				526				2,281				2,021
Mortgage banking income			17,493				20,875				58,587				59,162
Other			727				283				1,580				921
Total noninterest income			19,290				22,302				63,758				63,728
Noninterest expenses:
Compensation, payroll taxes, and other employee benefits			20,159				20,534				61,975				58,702
Occupancy, office furniture, and equipment			1,751				1,688				5,287				5,370
Advertising			605				712				1,949				2,181
Data processing			1,318				1,210				3,855				3,735
Communications			281				249				765				741
Professional fees			354				380				1,037				2,616
Real estate owned			(31	)			4				(2	)			(14	)
Loan processing expense			696				688				2,542				2,425
Other			2,529				2,001				7,508				6,437
Total noninterest expenses			27,662				27,466				84,916				82,193
Income before income taxes			7,601				9,844				25,788				23,394
Income tax expense			1,427				1,918				5,155				4,705
Net income		$	6,174			$	7,926			$	20,633			$	18,689
Income per share:
Basic		$	0.36			$	0.45			$	1.20			$	1.04
Diluted		$	0.36			$	0.45			$	1.19			$	1.04
Weighted average shares outstanding:
Basic			17,104				17,639				17,196				17,962
Diluted			17,189				17,671				17,270				17,985

WATERSTONE FINANCIAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
		September 30,				December 31,
		2026				2025
		(Unaudited)
Assets		(In Thousands, except per share amounts)
Cash		$	48,769			$	63,560
Federal funds sold			5,843				7,255
Interest-earning deposits in other financial institutions and other short term investments			291				292
Cash and cash equivalents			54,903				71,107
Securities available for sale (at fair value)			238,139				230,848
Loans held for sale (at fair value)			111,014				145,057
Loans receivable			1,698,019				1,675,552
Less: Allowance for credit losses (“ACL”) – loans			17,762				17,478
Loans receivable, net			1,680,257				1,658,074
Office properties and equipment, net			18,804				18,855
Federal Home Loan Bank stock (at cost)			17,161				19,804
Cash surrender value of life insurance			79,814				77,353
Real estate owned, net			934				424
Prepaid expenses and other assets			52,006				37,985
Total assets		$	2,253,032			$	2,259,507
Liabilities and Shareholders’ Equity
Liabilities:
Demand deposits		$	179,705			$	175,595
Money market and savings deposits			344,187				329,031
Time deposits			915,574				932,646
Total deposits			1,439,466				1,437,272
Borrowings			391,343				412,258
Advance payments by borrowers for taxes			25,608				2,996
Other liabilities			49,679				57,589
Total liabilities			1,906,096				1,910,115
Shareholders’ equity:
Preferred stock			–				–
Common stock			180				184
Additional paid-in capital			72,232				78,014
Retained earnings			304,881				292,957
Unearned ESOP shares			(8,605	)			(9,496	)
Accumulated other comprehensive loss, net of taxes			(21,752	)			(12,267	)
Total shareholders’ equity			346,936				349,392
Total liabilities and shareholders’ equity		$	2,253,032			$	2,259,507
Share Information
Shares outstanding			17,988				18,360
Book value per share		$	19.29			$	19.03

WATERSTONE FINANCIAL, INC. AND SUBSIDIARIES SUMMARY OF KEY QUARTERLY FINANCIAL DATA (Unaudited)
		At or For the Three Months Ended
		September 30,				June 30,				March 31,				December 31,				September 30,
		2026				2026				2026				2025				2025
		(Dollars in Thousands, except per share amounts)
Condensed Results of Operations:
Net interest income		$	16,416			$	16,010			$	15,463			$	15,711			$	14,739
Provision (credit) for credit losses			443				236				264				(558	)			(269	)
Total noninterest income			19,290				24,240				20,228				21,459				22,302
Total noninterest expense			27,662				29,379				27,875				27,677				27,466
Income before income taxes			7,601				10,635				7,552				10,051				9,844
Income tax expense			1,427				2,173				1,555				2,338				1,918
Net income		$	6,174			$	8,462			$	5,997			$	7,713			$	7,926
Income per share – basic		$	0.36			$	0.49			$	0.35			$	0.44			$	0.45
Income per share – diluted		$	0.36			$	0.49			$	0.34			$	0.44			$	0.45
Dividends declared per common share		$	0.17			$	0.17			$	0.17			$	0.15			$	0.15
Performance Ratios (annualized):
Return on average assets – QTD			1.09	%			1.52	%			1.10	%			1.35	%			1.42	%
Return on average equity – QTD			6.93	%			9.65	%			6.88	%			8.74	%			9.14	%
Net interest margin – QTD			3.06	%			3.03	%			2.97	%			2.89	%			2.76	%
Return on average assets – YTD			1.24	%			1.31	%			1.10	%			1.19	%			1.13	%
Return on average equity – YTD			7.82	%			8.26	%			6.88	%			7.62	%			7.23	%
Net interest margin – YTD			3.02	%			3.00	%			2.97	%			2.68	%			2.61	%
Asset Quality Ratios:
Past due loans to total loans			0.81	%			0.63	%			0.58	%			0.86	%			0.50	%
Nonaccrual loans to total loans			0.68	%			0.39	%			0.44	%			0.37	%			0.35	%
Nonperforming assets to total assets			0.55	%			0.30	%			0.35	%			0.29	%			0.27	%
Allowance for credit losses – loans to loans receivable			1.05	%			1.06	%			1.05	%			1.04	%			1.03	%

WATERSTONE FINANCIAL, INC. AND SUBSIDIARIES SUMMARY OF QUARTERLY AVERAGE BALANCES AND YIELD/COSTS (Unaudited)
		At or For the Three Months Ended
		September 30,				June 30,				March 31,				December 31,				September 30,
		2026				2026				2026				2025				2025
Average balances		(Dollars in Thousands)
Interest-earning assets
Loans receivable and held for sale		$	1,804,340			$	1,799,170			$	1,788,736			$	1,842,908			$	1,809,600
Mortgage related securities			184,800				185,513				183,980				180,434				178,063
Debt securities, federal funds sold and short term investments			139,186				136,901				137,861				133,781				131,165
Total interest-earning assets			2,128,326				2,121,584				2,110,577				2,157,123				2,118,828
Noninterest-earning assets			112,180				109,031				108,366				107,462				103,434
Total assets		$	2,240,506			$	2,230,615			$	2,218,943			$	2,264,585			$	2,222,262
Interest-bearing liabilities
Demand accounts		$	94,151			$	93,170			$	90,133			$	92,292			$	90,015
Money market, savings, and escrow accounts			370,761				354,112				343,416				339,368				334,300
Certificates of deposit – retail			822,452				817,261				817,019				823,586				823,274
Certificates of deposit – brokered			80,366				86,441				110,192				105,496				61,814
Total interest-bearing deposits			1,367,730				1,350,984				1,360,760				1,360,742				1,309,403
Borrowings			388,730				399,510				377,438				419,541				440,968
Total interest-bearing liabilities			1,756,460				1,750,494				1,738,198				1,780,283				1,750,371
Noninterest-bearing demand deposits			86,908				87,072				88,975				89,673				88,799
Noninterest-bearing liabilities			43,778				41,506				38,073				44,688				39,136
Total liabilities			1,887,146				1,879,072				1,865,246				1,914,644				1,878,306
Equity			353,360				351,543				353,697				349,941				343,956
Total liabilities and equity		$	2,240,506			$	2,230,615			$	2,218,943			$	2,264,585			$	2,222,262
Average Yield/Costs (annualized)
Loans receivable and held for sale			5.93	%			5.93	%			5.88	%			5.85	%			5.84	%
Mortgage related securities			3.23	%			3.20	%			3.21	%			3.09	%			3.04	%
Debt securities, federal funds sold and short term investments			4.51	%			4.39	%			4.74	%			4.54	%			4.74	%
Total interest-earning assets			5.60	%			5.59	%			5.58	%			5.54	%			5.53	%
Demand accounts			0.11	%			0.11	%			0.11	%			0.11	%			0.11	%
Money market and savings accounts			2.13	%			2.16	%			2.25	%			2.09	%			2.04	%
Certificates of deposit – retail			3.56	%			3.57	%			3.68	%			3.78	%			3.92	%
Certificates of deposit – brokered			3.85	%			3.81	%			3.82	%			3.89	%			4.11	%
Total interest-bearing deposits			2.95	%			2.98	%			3.09	%			3.12	%			3.19	%
Borrowings			3.51	%			3.56	%			3.42	%			3.51	%			3.86	%
Total interest-bearing liabilities			3.08	%			3.11	%			3.16	%			3.21	%			3.36	%

WATERSTONE FINANCIAL, INC. AND SUBSIDIARIES SUMMARY OF QUARTERLY AVERAGE LOAN BALANCES (Unaudited)
		September 30, 2026								June 30, 2026								September 30, 2025
		Ending Balance				Quarterly Average Balance				Ending Balance				Quarterly Average Balance				Ending Balance				Quarterly Average Balance
		(Dollars in Thousands)
Loans Receivable Category
One- to four-family		$	450,887			$	453,534			$	460,495			$	464,384			$	506,758			$	503,112
Over four family			810,524				802,369				781,860				773,593				769,325				740,220
Home equity			12,544				12,994				12,939				13,165				13,382				13,686
Construction and land			59,239				61,681				67,944				65,428				69,152				67,678
Commercial real estate			327,692				327,858				324,373				324,029				323,613				325,033
Consumer Loans			692				675				680				694				938				849
Commercial business loans			36,441				35,996				35,590				35,357				31,668				31,322
Total		$	1,698,019			$	1,695,107			$	1,683,881			$	1,676,650			$	1,714,836			$	1,681,900

COMMUNITY BANKING SEGMENT SUMMARY OF KEY QUARTERLY FINANCIAL DATA (Unaudited)
		At or For the Three Months Ended
		September 30,				June 30,				March 31,				December 31,				September 30,
		2026				2026				2026				2025				2025
		(Dollars in Thousands)
Condensed Results of Operations:
Net interest income		$	16,025			$	15,830			$	15,226			$	15,521			$	14,617
Provision (credit) for credit losses			488				249				284				(518	)			(276	)
Total noninterest income			1,311				2,020				1,153				1,305				1,359
Noninterest expenses:
Compensation, payroll taxes, and other employee benefits			5,639				5,612				5,575				5,646				5,036
Occupancy, office furniture and equipment			1,020				942				1,103				1,026				907
Advertising			165				251				212				250				213
Data processing			718				722				765				741				733
Communications			113				105				112				103				108
Professional fees			199				197				228				185				200
Real estate owned			(31	)			27				2				(298	)			4
Loan processing expense			–				–				–				–				–
Other			767				741				598				630				617
Total noninterest expense			8,590				8,597				8,595				8,283				7,818
Income before income taxes			8,258				9,004				7,500				9,061				8,434
Income tax expense			1,685				1,741				1,538				2,063				1,518
Net income		$	6,573			$	7,263			$	5,962			$	6,998			$	6,916
Efficiency ratio – QTD (non-GAAP)			49.55	%			48.16	%			52.48	%			49.23	%			48.94	%
Efficiency ratio – YTD (non-GAAP)			50.00	%			50.23	%			52.48	%			51.76	%			52.71	%

MORTGAGE BANKING SEGMENT SUMMARY OF KEY QUARTERLY FINANCIAL DATA (Unaudited)
		At or For the Three Months Ended
		September 30,				June 30,				March 31,				December 31,				September 30,
		2026				2026				2026				2025				2025
		(Dollars in Thousands)
Condensed Results of Operations:
Net interest income		$	351			$	164			$	214			$	205			$	103
Provision (credit) for credit losses			(45	)			(12	)			(20	)			(40	)			7
Total noninterest income			18,171				22,363				19,121				20,172				20,985
Noninterest expenses:
Compensation, payroll taxes, and other employee benefits			14,723				16,565				14,471				15,489				15,716
Occupancy, office furniture and equipment			731				628				863				798				781
Advertising			440				476				405				446				499
Data processing			600				557				490				465				475
Communications			168				121				146				129				141
Professional fees			155				103				152				33				180
Real estate owned			–				–				–				–				–
Loan processing expense			696				817				1,029				571				688
Other			1,808				1,676				1,777				1,586				1,271
Total noninterest expense			19,321				20,943				19,333				19,517				19,751
Income (loss) before income taxes			(754	)			1,596				22				900				1,330
Income tax (benefit) expense			(280	)			425				10				244				382
Net (loss) income		$	(474	)		$	1,171			$	12			$	656			$	948
Efficiency ratio – QTD (non-GAAP)			104.31	%			92.97	%			99.99	%			95.78	%			93.66	%
Efficiency ratio – YTD (non-GAAP)			97.94	%			96.21	%			99.99	%			97.56	%			98.17	%
Loan originations		$	509,730			$	621,819			$	508,314			$	534,646			$	539,404
Purchase			90.4	%			88.6	%			73.9	%			78.9	%			90.1	%
Refinance			9.6	%			11.4	%			26.1	%			21.1	%			9.9	%
Gross margin on loans sold(1)			3.48	%			3.60	%			3.65	%			3.80	%			3.87	%

⁽¹⁾ Gross margin on loans sold equals mortgage banking income (excluding the change in interest rate lock value) divided by total loan originations

Contact:
Mark R. Gerke
Chief Financial Officer
414-459-4012
markgerke@wsbonline.com

Stockholders’ deficit narrowed 34% from June 30. The Company converted $987,000 of accrued compensation to equity and appointed Brent Nelson as Chief Executive Officer

SOUTHLAKE, Texas, Nov. 13, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTCQB: AMFN) (“American Fusion” or the “Company”), developer of the proprietary Texatron™ Fusion Engine™, today announced the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The Company also highlighted financial, operational and corporate progress during the quarter and in recent weeks.

During the third quarter, American Fusion strengthened its balance sheet and grew its intellectual property portfolio. It also invested in research and testing equipment and converted most of its accrued compensation obligations into long-term equity. After the quarter ended, the Company completed a leadership transition. It also raised additional capital as it prepares for the next phase of Texatron™ development and testing.

Third Quarter and Year-to-Date 2026 Financial Highlights

$1.55 million in financing year-to-date: Net cash provided by financing activities was $1,551,000 for the nine months ended September 30, 2026. This consisted of $1,071,000 from the Company’s fixed-price prepaid warrant facility and $480,000 from the sale of equity units to third-party investors at $0.05 to $0.07 per unit. Each unit included a warrant exercisable at $0.50 per share. Prepaid warrant funding in the third quarter alone totaled $446,000.

Total assets nearly doubled: Total assets increased to $372,313 at September 30, 2026, from $196,683 at June 30, 2026.

Liabilities reduced: Total liabilities declined approximately 21% to $1,473,333 at September 30, 2026, from $1,856,662 at June 30, 2026.

Stockholders’ deficit improved 34%: Total stockholders’ deficit improved to $(1,101,020) at September 30, 2026, from $(1,659,980) at June 30, 2026.

Patent portfolio expansion: Capitalized patent filing costs reached $166,992 for the nine months ended September 30, 2026, compared to $33,472 at June 30. This reflects a significant increase in new patent filings covering the Texatron™ platform.

Investment in testing infrastructure: The Company capitalized $44,169 of research and development testing equipment acquired for future projects.

Continued R&D investment: Research and development expense was $112,195 for the third quarter and $243,538 for the nine-month period.

Non-cash expense profile: Of the $1,399,778 in third quarter operating expenses, $764,752 (approximately 55%) was non-cash stock-based compensation, primarily for officer, director and advisory agreements.

Capital Structure and Governance

$986,958 of accrued compensation converted to equity: Effective September 30, 2026, twelve officers, directors, consultants and advisors agreed to exchange their rights to common stock compensation for newly designated Series C Convertible Preferred Stock. The exchange removed $986,958 of accrued compensation obligations and replaced them with equity. Series C shares generally cannot be converted into common stock until the later of full vesting and the earlier of (i) the 20th trading day after a national exchange listing or (ii) nine months after issuance. After that, conversions are spread over four quarters.

Share count held steady: Common shares outstanding were 1,619,034,363 at September 30, 2026. That is unchanged from June 30 and approximately 45% below the 2,954,801,029 shares outstanding at December 31, 2025. The reduction follows the court-ordered cancellation of 1.683 billion legacy shares earlier in the year.

Board strengthened: John Gerdin joined the Board of Directors on August 11, 2026. He brings board governance, corporate finance and capital markets experience.

Texas DSHS registration: On July 17, 2026, the Company received Certificate of Registration No. R54726 from the Texas Department of State Health Services. The registration covers twelve registered Texatron™ Fusion Engine™ research model classes ranging from 500 kW to 1 GW, for research and development activities at its authorized testing location in Lubbock, Texas. It remains effective through February 28, 2034. The registration authorizes research and development activities only and does not constitute certification of the Company’s technology or commercial performance.

Recent Developments

Leadership transition: On October 26, 2026, Brent Nelson, Executive Chairman since March 1, 2026, was appointed Chief Executive Officer and continues as Chairman of the Board. Richard C. Hawkins, the former Chief Executive Officer, was appointed Chief Administrative Officer.

Additional capital: In late October 2026, the Company received aggregate net financing of approximately $687,000 for the acquisition of a property for testing.

Independent technology review: As announced November 9, 2026, an independent third-party reviewer conducted an on-site evaluation of the Texatron™ platform. The Company anticipates receiving the reviewer’s final report before the end of November 2026.

North Texas facilities: The Company expects to complete the acquisition of its planned North Texas Ranch Facility before November 26, 2026, subject to customary closing requirements. Its previously executed factory and office leases are expected to commence in November 2026.

Proposed Restructuring of Consulting Notes

American Fusion is developing a proposed exchange of certain existing consulting-related notes associated with Pinnacle Consulting Services Inc. and CMB Communications for a new class of Series D Convertible Preferred Stock.

The proposed exchange is intended to replace the applicable debt obligations with equity. Completion remains subject to reconciliation of the outstanding note balances and prior assignments, execution of definitive agreements, and receipt of required corporate approvals.

Management Commentary

“The third quarter was about building a stronger foundation,” said Brent Nelson, Chairman and CEO of American Fusion. “We meaningfully expanded our patent portfolio, invested in testing equipment and moved nearly $1 million of accrued compensation off our balance sheet and into long-term equity. That equity is aligned with the success of our shareholders. Our stockholders’ deficit improved by roughly a third in a single quarter.”

“With the independent technology review underway, our Texas registration in place and our North Texas facilities coming online, we are focused on disciplined execution and transparent reporting as we advance the Texatron™ program,” Nelson continued.

Summary Financial Information (Unaudited)

	Three Months Ended Sept. 30, 2026			Nine Months Ended Sept. 30, 2026
Revenue	$	—		$	58,000
Gross profit	$	—		$	8,000
Operating expenses	$	1,399,778		$	2,733,032
Of which, non-cash stock-based compensation	$	764,752		$	1,407,414
Research and development (included above)	$	112,195		$	243,538
Net loss	$	(1,436,076	)	$	(2,800,078	)
Net cash provided by financing activities		—		$	1,551,000

	Sept. 30, 2026			June 30, 2026
Cash and cash equivalents	$	70,633		$	79,341
Intangible assets, net	$	180,742		$	48,472
Total assets	$	372,313		$	196,683
Total liabilities	$	1,473,333		$	1,856,662
Total stockholders’ deficit	$	(1,101,020	)	$	(1,659,980	)
Common shares outstanding		1,619,034,363			1,619,034,363

About American Fusion Inc.
American Fusion Inc. (OTCQB: AMFN) is an advanced energy platform company focused on the development and commercialization of next-generation fusion energy technologies. The Company is advancing the Texatron™ Fusion Engine™ aneutronic fusion platform, designed for modular, infrastructure-grade deployment across industrial, commercial, defense and grid-constrained applications.

The Company’s development strategy emphasizes system-level engineering, disciplined intellectual-property protection and scalable architectures intended to support long-term commercial operation, while maintaining a focus on capital discipline and transparent corporate governance.

For more information about American Fusion and its Texatron™ platform, please visit: americanfusionenergy.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements address the development, testing, validation and commercialization of the Texatron™ Fusion Engine™, the independent technology review and its timing, facility acquisitions and lease commencement, future financing and a potential national exchange listing, and the Company’s business plans. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “will” and similar expressions identify forward-looking statements.

These statements reflect current expectations and involve substantial risks and uncertainties. These include scientific and engineering performance, independent validation, financing, regulatory approvals, customer acceptance and market conditions. The Company has a limited operating history and did not generate revenue in the third quarter of 2026. It has incurred recurring losses and had a working capital deficit of $1,325,931 at September 30, 2026. Its financial statements disclose substantial doubt about its ability to continue as a going concern. Management has identified a material weakness in internal control over financial reporting, and disclosure controls and procedures were not effective as of September 30, 2026. The Company’s convertible notes, warrants, Series C Preferred Stock and stock-based compensation arrangements may result in significant dilution to existing stockholders, including through variable-price conversion features. The Texatron™ platform has not demonstrated fusion ignition, net energy gain or commercial electrical generation. Actual results may differ materially from those anticipated, including due to risks described in the Company’s SEC filings, including its Registration Statement on Form 10 filed March 12, 2026. Readers should not place undue reliance on forward-looking statements. American Fusion undertakes no obligation to update them except as required by law.

Corporate Communications

833-872-2636 ext. 730

ir@americanfusionenergy.com
info@americanfusionenergy.com
americanfusionenergy.com  

MERIDIAN, Idaho, Nov. 13, 2026 (GLOBE NEWSWIRE) — PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced results of operations for its second quarter of fiscal year 2027, which ended on September 30, 2026.

Second Quarter 2027 Overview:

• Revenue increased 14.1% to $1.75 million in the second quarter of fiscal year 2027 compared to the second quarter in the previous year.
• Gross margin decreased 60 basis points to 57.4% in the second quarter of fiscal year 2027 compared to the second quarter in the previous year.
• Net income before income tax provision was ($0.12 million) in the second quarter versus $0.0 million for the same quarter in the previous year.
• Cash on hand decreased $0.36 million to $2.32 million versus the balance at the beginning of the fiscal year.
• During the quarter, 195,711 shares were repurchased, for aggregate consideration of $282,853, with the intent of being canceled.

Mike Bledsoe, President, commented, “I am pleased that our hard work is starting to show up in the numbers. While we don’t typically provide guidance, we have good visibility for the quarter we are in now, due to the fulfillment stages of a large order, and expect revenue to be more than double that of last year’s comparable quarter. We are starting to gain traction in our key growth initiatives, specifically our investments in our sales team and our recently released our Drone Pathways program and expect these investments to show significant results going forward.”

Suzanne DeZego, Chief Operating Officer stated, “Our focus is on turning our investments in sales and product development into consistent execution. That means keeping our teams aligned around customer needs, supporting educators as they implement our programs, and managing expenses carefully as we pursue growth.”

For more information about PCS Edventures!, Inc., visit our website.

Company financial information and reports can be found at https://www.sec.gov

About PCS Edventures!, Inc.

PCS Edventures!, Inc. (“OTCPK: PCSV”) is a Meridian, Idaho, company that designs and delivers technology-rich products and services for the TK-12 market that develop 21st-century skills. PCS programs emphasize experiential learning in Science, Technology, Engineering, and Math (“STEM”). https://edventures.com/.

Forward-Looking Statements.

This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Press Release. This Press Release should be considered in light of the disclosures contained in the filings of PCS and its “forward-looking statements” in such filings that are contained in the United States Securities and Exchange Commission (the “SEC”) Edgar Archives at https://www.sec.gov.

Contact.

Investor Contact: Michael Bledsoe 1.800.429.3110, mikeb@edventures.com
Investor Relations Web Site: https://investors.edventures.com/